Botulism medical therapy
|
Botulism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Botulism medical therapy On the Web |
|
American Roentgen Ray Society Images of Botulism medical therapy |
|
Risk calculators and risk factors for Botulism medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Michael Maddaleni, B.S., Tarek Nafee, M.D. [2], Keanu Ngo[3], Hafiz M. Ahmed, M.D.[4]
Overview
The two pillars of botulism management are early passive immunization with botulinum antitoxin and meticulous supportive/critical care, particularly respiratory support. Clostridium botulinum is a bacterium; its neurotoxin (BoNT) produces the flaccid paralysis of botulism. Antitoxin neutralizes circulating toxin and limits further paralysis but does not reverse established paralysis. Administer it as early as possible, ideally within 24 hours; the greatest benefit occurs during the first 2 days of illness. Patients with progressing paralysis should receive antitoxin regardless of the time elapsed since symptom onset. Treatment should not wait for laboratory confirmation. With appropriate supportive care, including mechanical ventilation when required, almost all patients can survive.
General principles
- Contact the state/local health department (and, through them, the CDC) immediately when botulism is suspected, to arrange antitoxin and confirmatory testing.
- Treat suspected symptomatic botulism on clinical grounds without awaiting laboratory confirmation. Early antitoxin administration is associated with improved outcomes; treatment within the first 2 days is associated with shorter hospitalization and intensive care stays than later treatment. Presentation after 48 hours does not exclude a patient from treatment.
- Antitoxin does not reverse established paralysis; recovery requires regeneration of nerve terminals over weeks to months.
- Arrange diagnostic specimen collection with public-health authorities. Obtain serum before antitoxin administration when feasible, but do not delay treatment for specimen collection or laboratory results.[1]
Antitoxin therapy
Non-infant botulism (equine heptavalent antitoxin, BAT/HBAT)
Equine-derived heptavalent botulinum antitoxin (BAT) contains antibodies against toxin types A–G and is used for symptomatic botulism other than the usual intestinal-colonization infant botulism syndrome. It is obtained through public-health consultation coordinated by state or local health departments and CDC. Infants with foodborne botulism may require BAT; infant botulism caused by toxin types other than A or B may also be treated with BAT following consultation.
- Adult dose: one vial administered by intravenous infusion. Observe patients throughout BAT administration for hypersensitivity reactions. Ensure that personnel and medications needed to manage anaphylaxis are immediately available.
- Pediatric dose: for children aged 1–16 years, the labeled dose ranges from 20% to 100% of the adult dose according to weight. For infants younger than 1 year who require BAT, the labeled dose is 10% of the adult dose, regardless of weight. These infant BAT instructions should not be confused with BabyBIG treatment for intestinal-colonization infant botulism. Monitor children closely for progression of paralysis after treatment. A large toxin exposure may require more antitoxin than the weight-based dose provides; consider retreatment following expert consultation when the diagnosis is convincing and deterioration continues.
- Safety: BAT can cause hypersensitivity reactions, including anaphylaxis. The CDC guideline reports an anaphylaxis frequency below 2%. Routine skin testing before administration is not recommended. Personnel able to recognize and treat anaphylaxis should observe patients during administration, with epinephrine and antihistamines readily available. Serum sickness has also been reported.[1]
- A second BAT dose should not be administered routinely. Consider repeat treatment only when paralysis clearly continues to progress after the initial dose should have taken effect and confidence in the diagnosis remains high. Neurologic deterioration continuing for more than 1 day after treatment should also prompt evaluation for alternative diagnoses.
Infant botulism (human BIG-IV, BabyBIG)
For infant botulism caused by toxin type A or B in patients <1 year, use human-derived Botulism Immune Globulin Intravenous (BIG-IV; BabyBIG), obtained through the California Infant Botulism Treatment and Prevention Program.
- Distinguish intestinal-colonization infant botulism from foodborne toxin exposure in an infant. Infants with foodborne botulism should receive BAT under the guideline's treatment approach. Infant botulism caused by toxin types other than A or B may also be treated with BAT following consultation.[1]
Supportive and critical care
Supportive care is the cornerstone of management.
- Monitor respiratory and bulbar function frequently. Facial and bulbar weakness can obscure signs of respiratory distress, and hypoxemia or hypercapnia may appear late. Assess the need for airway protection and mechanical ventilation using clinical findings and serial objective measurements rather than relying on oxygen saturation alone.
- Severe disease may require weeks to months of mechanical ventilation, with fluid and nutritional support and treatment of complications.
- Perform serial neurologic examinations assessing cranial nerve function, swallowing, respiratory status, and limb strength. Increase assessment frequency in rapidly progressing disease and in patients with bulbar or respiratory symptoms who have not been intubated.
- Obtain serial respiratory measurements using spirometry, end-tidal carbon dioxide monitoring, blood gas analysis, or other appropriate methods. Facial weakness may prevent an adequate mouthpiece seal and require a mask interface.
- Monitor cardiac rhythm continuously and measure blood pressure frequently.
- Assess for urinary retention, constipation or ileus, dry eyes, and dry mouth. Provide bladder and bowel care and prevent complications including pressure injuries, venous thromboembolism, and hospital-acquired infections.
- Recognize that patients are usually cognitively intact despite profound paralysis. Establish a means of communication, explain procedures before performing them, and provide psychological support.
- Begin speech, physical, and occupational therapy as soon as feasible.[1]
Antimicrobial therapy
Antimicrobials do not treat the toxin-mediated neurologic illness. When a concurrent infection requires antibiotic treatment, weigh the benefits against potential adverse effects and monitor for clinical deterioration.[1][2]
- Aminoglycosides can aggravate neuromuscular weakness. Clindamycin may also impair neuromuscular transmission. Use these agents only after careful consideration and with appropriate monitoring when treatment of a concurrent infection requires them.[1]
- Wound botulism: management of the toxin-producing wound generally centers on debridement, with treatment individualized to the clinical circumstances. Antitoxin and supportive care remain necessary for the neurologic illness.
Other medications requiring caution
Magnesium, tetracyclines, and calcium should be administered only after careful consideration and with appropriate monitoring. Neuromuscular blocking agents should be avoided when possible or used only after assessment of the risks and with suitable monitoring.[1]
Investigational and adjunctive therapies
Guanidine and 3,4-diaminopyridine have been used in attempts to improve acetylcholine release, but clear clinical benefit has not been established. Plasma exchange has likewise not demonstrated clear benefit. These interventions should not be presented as established alternatives to antitoxin and supportive care. Activated charcoal has no established benefit in human botulism and may cause aspiration in patients with impaired swallowing or gag reflexes. It may also complicate ileus. Polyethylene glycol preparations proposed to accelerate intestinal toxin clearance have no demonstrated benefit.[3][1]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Rao AK, Sobel J, Chatham-Stephens K, Luquez C. Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021. MMWR Recomm Rep 2021;70(No. RR-2):1–30. DOI: https://doi.org/10.15585/mmwr.rr7002a1
- ↑ Carrillo-Marquez MA (2016). "Botulism". Pediatrics in Review. 37 (5): 183–192. doi:10.1542/pir.2015-0018.
- ↑ Chalk CH; Benstead TJ; Pound JD; Keezer MR (2019). "Medical Treatment for Botulism". Cochrane Database of Systematic Reviews. 4: CD008123. doi:10.1002/14651858.CD008123.pub4.